200 € Bonus für Neukunden bei finanzen.net ZERO

Nur noch wenige Tage: Jetzt Depot bei unserem Broker eröffnen und Doppelbonus sichern!

Geschenkt: aktien-Magazin der 'Nvidia-Entdecker' (Wert: 147 €)

50 € Cash on top

Starte jetzt beim Kostensieger der Stiftung Warentest (12/2025)!

Jetzt informieren

Intellia Therapeutics Aktie

9,64 EUR +0,01 EUR +0,10 %

16:40:06

XETRA

11,17 USD +0,21 USD +1,87 %

17:21:24

BTT

Intellia Therapeutics jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Marktkap.1,37 Mrd. EUR

Div. Rendite0,00%

WKNA2AG6H

ISINUS45826J1051

SymbolNTLA

Intellia Therapeutics Aktien News

Sortieren:Datum Meistgelesen

14:20ZacksIntellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates

20.06.26MotleyFoolIntellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?

16.06.26ZacksStrength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?

WerbungIntellia Therapeutics-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

10.06.26ZacksIntellia Therapeutics (NTLA) Down 7.9% Since Last Earnings Report: Can It Rebound?

27.05.26ZacksADMA vs Intellia Therapeutics: Which Biotech Stock Is a Better Pick Now?

11.05.26ZacksIntellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Misses Revenue Estimates

07.05.26ZacksIntellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

27.04.26BenzingaIntellia Therapeutics FDA Rolling Application For Gene Therapy Puts Hype To Test

03.03.26BenzingaDemystifying Intellia Therapeutics: Insights From 4 Analyst Reviews

02.03.26BenzingaIntellia Therapeutics Stock Gains — FDA Lifts Clinical Hold On Pivotal Trial

26.02.26ZacksIntellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates

25.02.26BenzingaEarnings Preview For Intellia Therapeutics

28.01.26BenzingaBreaking Down Intellia Therapeutics: 11 Analysts Share Their Views

28.01.26ZacksIntellia Therapeutics (NTLA) Surges 6.3%: Is This an Indication of Further Gains?

14.01.26ZacksIntellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 200-Day Moving Average

11.11.25BenzingaWhat 21 Analyst Ratings Have To Say About Intellia Therapeutics

06.11.25ZacksIntellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Misses Revenue Estimates

29.10.25BenzingaIntellia Therapeutics Stock Is Diving Again: Here's Why

09.10.25ZacksIntellia Therapeutics (NTLA) Soars 19.7%: Is Further Upside Left in the Stock?

08.10.25ZacksIntellia Therapeutics (NTLA) Upgraded to Buy: Here's What You Should Know

08.10.25ZacksWall Street Analysts Predict a 63.7% Upside in Intellia Therapeutics (NTLA): Here's What You Should Know

08.10.25ZacksIs Intellia Therapeutics (NTLA) Outperforming Other Medical Stocks This Year?

06.10.25BenzingaWhat Analysts Are Saying About Intellia Therapeutics Stock

19.09.25ZacksStrength Seen in Intellia Therapeutics (NTLA): Can Its 29.8% Jump Turn into More Strength?

19.09.25BenzingaExpert Outlook: Intellia Therapeutics Through The Eyes Of 5 Analysts

18.09.25BenzingaIntellia Therapeutics Shares Are Ripping Higher: Here's Why

11.08.25BenzingaDemystifying Intellia Therapeutics: Insights From 9 Analyst Reviews

07.08.25ZacksIntellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Beats Revenue Estimates

23.04.25PR NewswireLawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

08.04.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - NTLA

08.04.25PR NewswireClass Action Filed Against Intellia Therapeutics, Inc. (NTLA) Seeking Recovery for Investors - Contact Levi & Korsinsky

07.04.25PR NewswireNTLA Investors are reminded of Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

31.03.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLA

25.03.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLA

25.03.25PR NewswireNTLA Investors are reminded of Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

20.03.25PR NewswireNTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit

17.03.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLA

04.03.25PR NewswireLevi & Korsinsky Reminds Intellia Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - NTLA

03.03.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLA

03.03.25PR NewswireNTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit

Intellia Therapeutics News

Intellia Therapeutics News: auf dieser Seite finden Sie alle Intellia Therapeutics News und Nachrichten zur Intellia Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Intellia Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Intellia Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.